Tissue-based immune monitoring II

The presence of tumor-infiltrating lymphocytes (TILs) in epithelial ovarian cancer indicates a host antitumor response and is associated with improved survival. We wished to determine the extent to which TIL density differs from site to site within a given patient. We initially studied multiple paired metastases from serous ovarian carcinoma obtained at the time of primary debulking. The expression of genes in specific immune-related pathways was profiled on a pilot set of five patients. We then used immunohistochemistry and quantitative PCR to estimate the density of CD3+, CD8+, and FoxP3+ TILs in these same tumors. To extend the findings to a larger cohort, we semiquantitatively measured intraepithelial and stromal TILs in a tissue microarray (TMA) containing both primary tumors and metastases from 50 patients. In the pilot group, genes related to antimicrobial signaling and TGF-beta signaling showed between-site heterogeneity, whereas cytokines and antigen presentation transcripts were more homogeneous in any given patient. IHC and qPCR for T cell markers were concordant. In the TMA cohort, 2-way ANOVA showed that TIL heterogeneity between sites was present in some but not all patients. The stroma of extra-ovarian metastases showed significantly greater TIL infiltration than ovarian sites. A simulation showed that at clinically meaningful levels of precision, up to 3% of patients will be misclassified for intraepithelial TILs by a single biopsy. In conclusion, between-site heterogeneity exists in some patients with metastatic serous ovarian cancer. The predictive value of biopsies should be considered in clinical trial design.

[1]  A. Sood,et al.  Field cancerization: why late "recurrent" ovarian cancer is not recurrent. , 1998, American journal of obstetrics and gynecology.

[2]  Yudi Pawitan,et al.  Normalization of oligonucleotide arrays based on the least-variant set of genes , 2008, BMC Bioinformatics.

[3]  P. Lipponen,et al.  Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. , 1994, European journal of cancer.

[4]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[5]  N. Urban,et al.  Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  I. Šteiner,et al.  Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. , 2008, Gynecologic oncology.

[7]  R. Berkowitz,et al.  Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. , 1995, Cancer research.

[8]  M. Werner,et al.  Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes , 2009, British Journal of Cancer.

[9]  R. Sokal,et al.  THE COMPARISON OF DENDROGRAMS BY OBJECTIVE METHODS , 1962 .

[10]  T. Schuster,et al.  Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. , 2009, Human gene therapy.

[11]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[12]  S. Rosenberg,et al.  Adoptive cell transfer therapy. , 2007, Seminars in oncology.

[13]  G. Rabinovich,et al.  Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment , 2007, Cancer Immunology, Immunotherapy.

[14]  G. Linette,et al.  Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity , 2005, Clinical Cancer Research.

[15]  F. Ramsdell,et al.  Foxp3 and natural regulatory T cells: key to a cell lineage? , 2003, Immunity.

[16]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[17]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[18]  S. Rosenberg,et al.  Cancer immunotherapy: moving beyond current vaccines , 2004, Nature Medicine.

[19]  P. Gimotty,et al.  Intraepithelial T cells and tumor proliferation , 2009, Cancer.

[20]  H. Lyerly,et al.  Assays for monitoring cellular immune responses to active immunotherapy of cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  J. Kirkwood,et al.  Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Schlag,et al.  Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.

[23]  Joanna H Shih,et al.  Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways , 2004, Oncogene.

[24]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[26]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[27]  J. Leonard,et al.  Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H Nagura,et al.  Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. , 2001, Cancer research.

[30]  A. Marrogi,et al.  Study of tumor infiltrating lymphocytes and transforming growth factor‐β as prognostic factors in breast carcinoma , 1997, International journal of cancer.

[31]  C. Slingluff,et al.  A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer , 2008, Journal of immunotherapy.

[32]  I. Jacobs,et al.  Genetic intra‐tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours , 2007, The Journal of pathology.

[33]  H. Nisenbaum,et al.  Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. , 2007, Cancer research.

[34]  Dongxia Gao,et al.  Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors , 2009, PloS one.

[35]  J. Kelley,et al.  A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer , 2010, Cancer Immunology, Immunotherapy.

[36]  George Coukos,et al.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.

[37]  G. Coukos,et al.  TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  Yoshimasa Tanaka,et al.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer , 2007, Proceedings of the National Academy of Sciences.

[39]  M. Banerjee,et al.  Interleukin-2 administration alters the CD4+FOXP3+ T-cell pool and tumor trafficking in patients with ovarian carcinoma. , 2007, Cancer research.

[40]  S. H. van der Burg,et al.  Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial , 2009, International journal of cancer.

[41]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[42]  Naveena Singh,et al.  The clonal evolution of metastases from primary serous epithelial ovarian cancers , 2009, International journal of cancer.

[43]  R. Berkowitz,et al.  Molecular genetic evidence of a unifocal origin for human serous ovarian carcinomas. , 1993, Gynecologic oncology.

[44]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[45]  Rochelle L. Garcia,et al.  Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer. , 2008, Gynecologic oncology.

[46]  Matt van de Rijn,et al.  Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss , 2009, Modern Pathology.